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Editorial on the Research Topic
Sepsis in Neonates and Children
INTRODUCTION
Sepsis, defined as life-threatening organ dysfunction resulting from dysregulated host response
to infection, affects over 25 million children every year, causing an estimated 3 million deaths in
neonates, children and adolescents globally (1). The life-time incidence of sepsis is strongly age-
dependent, with highest rates observed in preterm neonates, followed by neonates, infants, and
children (2).
Specific challenges have traditionally hindered progress in the field of sepsis in children
(3). Albeit epidemiology is often split into neonatal and pediatric age groups, the evidence to
support the traditional 1-month-of-age cut-off stands on shaky grounds. Sepsis in very preterm
neonates exposed to multiple iatrogenic risks likely represents a very distinct disease from
vertically transmitted early-onset-sepsis in a term newborn, pneumococcal sepsis in a young infant,
hospital-acquired sepsis in a neutropenic child, or staphylococcal toxic shock in an adolescent
patient. Accurate characterization of the disease remains problematic, even if the Sepsis-3 concept
of suspected or confirmed infection with organ dysfunction is in principle applicable to the
pediatric and neonatal population (4). Similar to adults, there is a discrepancy between the global
distribution of sepsis burden and the high income settings where the majority of sepsis research
has been performed. In addition, ethical challenges relating to consent processes and enrolment of
critically ill patients can represent obstacles to conduct interventional studies, and blood sampling
availability for research faces particular challenges in young children. Finally, in 2020, too many
children receive antibiotics, but too many still die from infection. We have to emphasize the
importance of early detection and risk stratification, prompt administration of antimicrobials, rapid
resuscitation, and supportive care for organ dysfunction (5).
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The aim of the Frontiers in Pediatrics Research Topic
“Sepsis in Neonates and Children” was to collect state-of-the art
articles and reviews highlighting the challenges, obstacles, and
opportunities in assessing sepsis burden, understanding sepsis,
and improving sepsis outcomes in neonates and children. We
hereby provide an overview of this Frontiers in Pediatrics topic
which includes 10 original articles, 9 review articles, 2 systematic
reviews, and 1 perspective article.
PATHOPHYSIOLOGY OF SEPSIS: NEW
INSIGHTS AND CLINICAL IMPLICATIONS
The autonomic nervous system (ANS) regulates the functions of
many organ systems, responding to stressors such as infection.
Badke et al. reviewed the evidence supporting the key role
of the ANS response to infection, and the importance of
ANS dysfunction in the pathophysiology of sepsis. The ANS
is activated early on during infection by afferent fibers which
sense pathogens and tissue damage. Such activation can be
assessed by changes in heart rate variability which have been
shown to be associated with organ dysfunction and death in
adults and children. Hence, non-invasive monitoring of heart
rate characteristics represents a promising early warning tool to
detect sepsis, and is associated with reduced mortality in preterm
newborns (6).
Sensing of pathogens and tissue damage leads to rapid
alterations of innate and adaptive immune responses,
complement and coagulation, vascular, neuronal, metabolic,
and endocrine systems. The early peak mortality in sepsis
is associated with overwhelming inflammation and organ
dysfunction seen across all age groups. At the same time,
sepsis-induced immune suppression, a state characterized by
exhaustion of innate and adaptive immune responses has been
described in adults, leading to impaired pathogen clearance,
reactivation of latent viral infections, nosocomial infections
and late mortality (7). A limited capacity to mount efficient
immune response mediates the increased susceptibility to
infection observed in newborns (8) and is likely affected by
suppression by immune cells, erythroid cells, and placental
mediators. Contrary to the traditional belief that the neonatal
immune system is primarily characterized by anergy or low
function, newborns can in fact display dysregulated immune
responses associated with excessive inflammation and early
death (9). Hibbert et al. reviewed the evidence suggesting that
sepsis may induce immune suppression in neonates or aggravate
a preexisting state of developmental immune suppression. A
better understanding of the biological pheno-or endotypes of
newborns and children with sepsis will open avenues for future
immune modulating strategies.
Gestational age and postnatal maturation are important
determinants of the developmental state of immune responses,
with the evolvingmicrobiome and interaction with host nutrition
having a strong influence (10). Schüller et al. reviewed distinct
phenotypes of the developing neonatal immune system, and
the immunological characteristics that may be implicated with
the increased susceptibility to infection observed in early-life.
They review immune modulating therapies to prevent and treat
neonatal sepsis and emphasize the importance of human milk to
prevent neonatal and infant sepsis (11, 12). This field is rapidly
evolving, as illustrated by current studies to optimize dose and
test efficacy and safety of pentoxifylline in treatment of neonatal
sepsis (Clinical Trials NCT04152980, ACTRN12616000405415).
The findings presented should be considered as well in view
of meta-analyses on enteral supplementation with probiotics to
reduce rates of NEC, late-onset sepsis and all-cause mortality
in very preterm newborns (13). While evidence for efficacy is
strong, there are still open questions regarding the selection
of probiotic strains, dose, duration of treatment, and quality
control of available products (14). In this context, the study
by Esaiassen et al. evaluates the influence of probiotics and
antibiotics on the developing gut microbiota and its antibiotic
resistome, defined as the collection of all antibiotic resistance
conferring genes. In their observational study, preterm infants
<28 weeks supplemented with probiotics had a higher exposure
to antibiotics compared to non-supplemented preterm (28–
31 weeks) and term infants. Interestingly, microbial diversity
and resistomes were not different between the three groups,
which may be interpreted that the probiotic strains reduce the
harmful effects of antibiotics on gut microbiota composition and
antibiotic resistome development.
EARLY DIAGNOSIS AND RISK
STRATIFICATION
In adults, Sepsis-3 differentiates sepsis from uncomplicated
infection by the presence of organ dysfunction (15). The
Sequential Organ Failure Assessment (SOFA) score has better
prognostic accuracy in adults compared to former sepsis criteria.
Age adapted pediatric (pSOFA) and neonatal (nSOFA) scores
have shown promising results in pediatric intensive care units
(PICUs) and neonatal intensive care units (NICUs) from high-
income countries. Yet applicability to global settings remains
controversial (16–18). Obonyo et al. discuss the challenges to
apply sepsis criteria to children cared for outside intensive
care, including emergency department (ED) and in low-and-
middle-income countries. The systematic review by Liang et al.
on clinical risk factors for mortality in neonates and infants
hospitalized for severe infection in low-and-middle-income
countries sheds further light on these challenges. In low-and
middle-income country studies, neonatal deaths were associated
with prematurity, low birthweight and low postnatal age, similar
to findings from high-income countries (19). In addition, absence
of breastfeeding, malnutrition and respiratory or cardiovascular
dysfunction were key risk factors. These findings may help
to stratify patients most likely to benefit from preventive and
targeted therapeutic interventions.
van Nassau et al. tested the accuracy of an age-adapted quick
SOFA score (qSOFA) to predict the combined outcome of death
and transfer to a PICU in children presenting to the ED for
suspected bacterial infection requiring admission to the hospital.
In their study, the proportion of children with critical illness
requiring admission to a PICU and mortality were very low, and
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the prognostic accuracy of qSOFA, SIRS and qPELOD-2 was only
modest. While the study cohort was small, the findings imply that
current sepsis criteria do not perform sufficiently well to enable
robust risk stratification of children with suspected bacterial
infection. Novel approaches based on prospective collection
of vital signs and laboratory values in large cohorts including
electronic health records are urgently needed. In this context,
it is important to consider that vital sign thresholds based
on normal values according to age are incorporated in most
recommendations and screening tools for risk stratification in the
ED. However, normal values for vital signs of children so far were
based on relatively small cohorts using traditional data capture
methods. Sepanski et al. accessed a database of over 1 million
medical records to provide a novel and reliable representation of
heart rate and respiratory rate distribution in children presenting
to the ED and who did not require hospitalization. This data
will be useful to develop new risk scores and disease screening
tools with increased sensitivity and specificity, to update current
guidelines and improve alarm limits for bedside monitors.
In children, sepsis most commonly occurs in the community
and the timing when parents seek medical care may influence
disease severity and outcomes. In this context, Harley et al.
reviewed the literature on the role of parental concerns in the
recognition of sepsis in children and underscored the paucity of
published data. Future studies are needed to develop evidence-
based tools incorporating parental assessment of severity,
parental decision-making in seeking medical care, and determine
the diagnostic value of parental concerns.
SEPSIS RESUSCITATION
Early identification and appropriate resuscitation and
management are critical to optimize outcome of children
with sepsis. The Surviving Sepsis Campaign recently published
updated guidelines for the management of septic shock in
children (20). In past as well as in the present guidelines, fluid
bolus therapy remains a first line cornerstone treatment for
resuscitation of pediatric septic shock. Gelbart reviewed the
current knowledge and challenges regarding fluid bolus therapy
in pediatric sepsis. While clinical signs, echocardiography and
other non-invasive and invasive monitoring tools are commonly
used to assess shock and define circulatory status, the accuracy
of these approaches to predict response to fluid boluses remains
very limited. Given an increasing body of literature documenting
potential harm related to excessive fluid therapy, restrictive fluid
resuscitation protocols such as early vasoactive support needs to
be investigated.
OPTIMIZATION OF ANTIBIOTIC USE
Administering the right antibiotic, at the right dosage to the right
patient and at the right time for the right duration remains a
challenge toward optimal management of patients with suspected
or proven infection. Antimicrobial stewardship (AMS) aims
at improving the safe and appropriate use of antimicrobials,
for better patient outcomes and reduction of antimicrobial
resistance. Steinmann et al. reviewed the literature on the impact
of leadership style on implementation and success of AMS and
infection prevention programs, and share their own experience in
a mixed NICU/PICU. A leadership style focused on empowering
staff to take responsibilities led to higher engagement of staff
and was associated with a reduction of antibiotic use and
nosocomial infections.
van Donge et al. explored the complex relation between
antibiotic regimen, exposure and response. Selecting the best
antibiotic regimen is particularity challenging for neonates, due
to rapid changes in drug metabolism and renal function during
the first days and weeks of life which altogether alter drug
distribution and elimination. Tauzin et al. presented a study
on exposure to vancomycin in neonates receiving continuous
drug infusion, and compared their results to those obtained
using simulations with different models. This study highlights
the challenges of prescribing a drug with a narrow therapeutic
margin, the need for therapeutic drug monitoring and the
importance of conducting pharmacokinetic studies.
Blood cultures remain a cornerstone of antibiotic stewardship
to streamline targeted treatment and reduce unnecessary
antibiotics. In most hospitals, children, and neonates with
suspected sepsis are empirically treated for at least 48 h awaiting
results of blood cultures, based on recommendations supported
by limited evidence. Dierig et al. presented an analysis of blood-
culture proven sepsis episodes in neonates and children included
in the Swiss Pediatric Sepsis Study. In this prospective national
cohort study, the median time to positivity, defined as the time
between placement of the blood culture bottle into the automated
system and a positive signal, was 12 h (IQR 8–17 h), and 88%, and
96%, of blood cultures were positive by 24 and 36 h, respectively.
These findings indicate that the decision to continue empiric
antibiotic treatment in the absence of positive blood culture
should be reconsidered already after 24–36 h.
Culture-negative sepsis designates presumed symptomatic
infection without a documented pathogen, and represents
a substantial proportion of episodes in patients treated for
presumed sepsis. Klingenberg et al. critically reviewed the entity
of culture negative neonatal early-onset sepsis and propose
strategies to improve AMS in early-life, without compromising
efficient care.
Biomarkers are commonly used in the clinic to guide
antibiotic treatment. In a prospective study conducted in two
NICUs, Dillenseger et al. measured circulating levels of CRP,
PCT, IL-6, and IL-8 at the time of clinical presentation, and
evaluated their diagnostic performance to identify newborns
with nosocomial sepsis. This study confirms previous studies
showing that—across all age groups—biomarkers used alone or
in combination have a limited value to help clinicians decide
whether or not to initiate antibiotic treatment (21, 22).
Ventilator-associated pneumonia (VAP) is amongst the
leading causes of nosocomial infection in intensive care units,
and account for a large proportion of antibiotic use in NICUs and
PICUs (23, 24). Diagnosis and confirmation of VAP is difficult
in neonates, which may result both in overtreatment and delays
in initiation of appropriate treatment with antibiotics. Goerens
et al. presented the results of a quality improvement initiative for
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neonatal VAP. The intervention based on a prevention bundle
and AMS interventions resulted in a decline in VAP incidence
and antibiotic use.
EPIDEMIOLOGY
The distribution of pathogens causing invasive infection evolves
over time and is influenced by the practices used to prevent
and treat infections. Epidemiological studies are important for
benchmarking and quality improvement, to update policies and
practices based on the most prevalent pathogens and their
susceptibility to antibiotics, and to identify patients at the highest
risk of developing infection and infection-related complications.
Conjugated meningococcal vaccines have had a tremendous
impact on reducing the incidence meningococcal sepsis and
meningitis. Yet, Neisseria meningitidis remains a major agent
causing sepsis and meningitis worldwide, and is associated
with significant mortality, and long term disability in many
survivors. Nadel and Ninis reviewed the preventive strategies,
clinical features, and management of invasive meningococcal
disease in the area of vaccination, highlighting the importance
of detection and early management of the disease to improve
patient outcome. Xu et al. reported on a cohort of term
newborns with meningitis in Shanghai. Group B Streptococcus
and Escherichia coli were the predominant pathogens. The high
proportion of patients with abnormal neurological examination
at discharge, abnormal magnetic resonance imaging and/or
withdrawal of treatment underscores the considerable burden
of disease. Furthermore, particular patient groups are much
more susceptible to sepsis, as illustrated by patients with sickle
cell disease. Increased blood viscosity and vascular occlusion
result in functional asplenia and immune deficiency, thereby
increasing susceptibility to bacterial infections. Ochocinski et al.
reviewed the life-threatening infectious complications of sickle
cell disease, and identified priorities for prevention and treatment
of infections in high- and low-income countries.
Toxic Shock Syndrome (TSS) is a severe acute illness
caused by toxin-producing strains of Staphylococcus aureus or
Streptococcus pyogenes. The study by Javouhey et al. shows that
Staphylococcus and Streptococcus TSS in children differ by their
source of infection, clinical presentation, disease severity and
outcome. Staphylococcus TSS predominantly originated from the
female genital tract, while Streptococcus TSS was associated with
pulmonary infection and bacteremia, a more frequent occurrence
of respiratory failure and a longer duration of mechanical
ventilation and stay in PICU.
Bacterial and fungal infections are most commonly attributed
as the cause of sepsis. However, viruses can trigger dysregulated
host responses, leading to life-threatening organ dysfunction as
illustrated by the current COVID-19 pandemic. Gupta et al.
summarized the epidemiology, pathophysiology and diagnostic
and therapeutic aspects of the management of viral sepsis. The
importance of early recognition and pathogen identification in
viral sepsis has important implications for AMS, infection control
measures, risk stratification, and in some cases antiviral therapies.
CONCLUSIONS
The striking impact of sepsis on child health indicates that
developmental aspects such as mode of transmission, pathogen
susceptibility, and host response, underpin the epidemiology of
childhood sepsis. A better understanding of the heterogeneity
of the disease, age-specific epidemiology and pathophysiology
remains a key requirement to prevent sepsis and reduce
disease severity, improve short and long term outcomes,
and lessen the burden for the society. To date, populational
data still compare predominantly “count” data on sepsis
cases and sepsis mortality, failing to take into account that
sepsis in children affects patients with a life expectancy of
up to 85 years, leading to a disproportional impact on
quality adjusted life years and years of life lost. There is
urgency for future studies to reflect on the whole-of-life
and whole-of-society impact of pediatric sepsis integrating
mortality, morbidity, long-term outcomes (25), and direct and
indirect costs.
The collection of articles on sepsis in this Frontiers Topic
highlights our current understanding, knowledge gaps and
limitations of approaches to prevent, diagnose, and treat sepsis,
and priorities for future research.
Key areas emerging as future research priorities include
first, prevention though enhanced hygiene, modulation of the
microbiome and nutritional strategies, and vaccines. Second,
there is a major need to better define the biological and
clinical phenotypes of neonates and children with sepsis enabling
reliable discrimination between children with uncomplicated
infection and those where infection leads to organ dysfunction
due to dysregulated host response. Third, deciphering the
heterogeneity of sepsis in neonates and children will enable
novel approaches for targeted individualized interventions more
likely to change disease trajectories in individual patients. The
increasing availability of biological (OMICs) and high resolution
clinical data from electronic health records and the rapid progress
in applying computational science to health data is likely to
change our approach to sepsis in children in the coming decades.
Integrative approaches may enhance clinical evaluation at the
bedside, and enable the development of artificial intelligence-
based sepsis recognition and risk stratification tools with the
ultimate view to deliver precision medicine. Forth, currently
available observational data indicate that the most substantial
outcome improvements in sepsis can be achieved by reliable
implementation of systems to systematically screen and treat
children with sepsis aiming to enhance reliability of sepsis care
across health care systems (3, 26). Finally, it is imperative that
sepsis campaigns work hand in hand with AMS initiatives to
reduce unnecessary exposure to antibiotics in children which do
not suffer from bacterial infections (5).
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